Clare Market Investments LLC Invests $1.35 Million in Cencora, Inc. (NYSE:COR)

Clare Market Investments LLC acquired a new position in Cencora, Inc. (NYSE:COR) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,000 shares of the company’s stock, valued at approximately $1,348,000.

Several other institutional investors have also recently made changes to their positions in COR. Pacer Advisors Inc. raised its stake in shares of Cencora by 6,855.3% in the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company’s stock worth $464,874,000 after buying an additional 2,035,679 shares during the period. Raymond James Financial Inc. bought a new position in shares of Cencora in the fourth quarter worth about $322,460,000. Wellington Management Group LLP raised its stake in shares of Cencora by 7.0% in the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company’s stock worth $1,168,927,000 after buying an additional 338,452 shares during the period. Amundi raised its stake in shares of Cencora by 30.8% in the fourth quarter. Amundi now owns 1,338,710 shares of the company’s stock worth $318,385,000 after buying an additional 314,846 shares during the period. Finally, Nordea Investment Management AB raised its stake in shares of Cencora by 40.2% in the fourth quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company’s stock worth $243,173,000 after buying an additional 308,773 shares during the period. Institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the transaction, the chief executive officer now owns 51,070 shares of the company’s stock, valued at approximately $13,022,850. This trade represents a 8.87 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,648 shares of company stock worth $2,862,342. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Performance

NYSE:COR opened at $254.54 on Monday. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $262.26. The stock’s 50 day simple moving average is $244.34 and its two-hundred day simple moving average is $238.39. The company has a market cap of $49.36 billion, a price-to-earnings ratio of 36.21, a PEG ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is 31.29%.

Analyst Ratings Changes

Several brokerages recently issued reports on COR. Wells Fargo & Company lifted their target price on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Mizuho began coverage on Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Finally, StockNews.com downgraded Cencora from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.